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Introduction
Ventilation of ARDS patients with low tidal volume (Vt)
is performed in order to minimize ventilation induced
lung injury. This strategy, however, may induce hyper-
capnic acidosis, promote derecruitment and, in some
individuals, induce alveolar overdistention despite the
use of low Vt. Extracorporeal CO2 removal can help
minimizing hypercapnic acidosis and to further reduce
Vt (i.e. ultraprotective ventilation).
Objectives
To evaluate the effect of extracorporeal CO2 removal in
ARDS during ultraprotective ventilation in terms of lung
mechanics and gas exchange.
Methods
We studied 9 ARDS patients, in whom ultraprotective ven-
tilation (i.e. Vt 4 ml/kg PBW) was implemented by means
of an extracorporeal CO2 removal system [Hemolung
®
Respiratory Assist System (RAS), ALung, Pittsburgh].
Anticoagulation with unfractionated heparin to reach an
aPTT target range of 1.5-2 was used. We compared base-
line ventilation with ultraprotective ventilation (combining
Vt of 4 ml/kg PBW and Hemolung®), in terms of lung
mechanics and gas exchange. We collected arterial blood
gases, respiratory and hemodynamic variables, and mixed
expired gases at baseline and after 60 minutes of stabiliza-
tion at ultraprotective ventilation. Statistical analysis:
2-tailed Student’s t-test. Statistical significance p < 0.05.
Results
Fivemen and fourwomenwithARDSwhere studied (8 pneu-
monias and 1 abdominal sepsis). Age was 61 ± 14 years,
SAPS II at admission 48 ± 28 and ICU mortality 22% (2/9).
Seven of these patients were treated with prone positioning
during mechanical ventilation. Cannulation was done via
femoral vein in all patients, using “ad hoc” 15.5 Fr catheters.
Hemolung® allowed a CO2 removal rate of 84 ± 9 mL/min,
with blood flow 447 ± 35 mL/min, at constant sweep gas
flow (10 L/min of O2) and pump speed (1400 RPM).
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Table 1.
VARIABLE BASELINE 4ml/kg PBW + Hemolung® T-TEST p
Vt (mL/kg PBW) 6.4 ± 1 4 ± 0 < 0.001
Vt (mL) 374 ± 55 238 ± 47 < 0.001
RR (bpm) 24 ± 3 28 ± 6 0.027
VE (ml/min) [=Vt*RR] 8798 ± 1297 6639 ± 1679 0.004
PEEP (cmH2O) 11 ± 1 13 ± 4 0.227
Pplat (cmH2O) 24 ± 4 22 ± 3 0.074
Crs (mL/cmH2O) [=Vt/Pplat-PEEP] 30 ± 9 30 ± 11 0.998
ΔP [cmH2O] [=Pplat-PEEP] 13 ± 3 9 ± 6 0.003
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Unfractionated heparin dose was 200 ± 78 mg/day and
aPTT was 1,56 ± 0.18. During catheter insertion a bolus
of 0.6 ± 0.2 mg/kg mg was administered. Hemolung®
total days were 5.3 ± 6.2 (range 1 to 22). No significant
haemorrhage or hemolysis needing transfusion, device
malfunction, insertion and/or withdrawal complications
occurred. We report a significant reduction in minute
ventilation and alveolar minute ventilation (75% and
66%, respectively), dead space (68%), and driving pres-
sure (69%), without significant changes in arterial blood
gases when ultraprotective strategy was implemented, as
compared to baseline (see tables 1 and 2).
Conclusions
Hemolung® system allows ultraprotective ventilation,
while maintaining adequate arterial blood gases and sig-
nificantly decreasing the intensity of ventilator assis-
tance. The technique appears to be useful and safe.
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Table 2.
VARIABLE BASELINE 4ml/kg PBW + Hemolung® T-TEST p
Vd (mL) [=(PaCO2-PECO2/PaCO2] 262 ± 29 175 ± 27 < 0.001
Vd/Vt 0.71 ± 0.06 0.75 ± 0.09 0.219
Va min (mL/min) [=(Vt-Vd)*RR] 2614 ± 771 1718 ± 856 0.028
FiO2 0.6 ± 0.2 0.6 ± 0.1 0.420
pH 7.38 ± 0.06 7.35 ± 0.11 0.493
PaO2 (mmHg) 91 ± 21 109 ± 28 0.138
PaCO2 (mmHg) 50 ± 19 49 ± 12 0.919
MAP (mmHg) 79 ± 18 75 ± 14 0.332
HR (bpm) 101 ± 26 92 ± 22 0.048
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